Molecular evolution of hepatitis C virus in China: A nationwide study

Huang, Ke; Chen, J; Xu, Ru; Jiang, Xuemei; Jia, Ming; Wang, M; Huang, Jieting; Liao, Qiao; Shan, Zhengang; Dailey, Cody; Song, Xiaomu; Lü, Ling; Li, C; Xiao, Rong; Zhang, M; Fu, Yongshui

doi:10.1016/j.virol.2018.01.015

Cited by 15 publications

(21 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HCV infection in China has showed a steady decrease from an average 3.2% in 1992 to 0.36% in 2010[64]. HCV genotypes 1b and 2a are predominant in China, whereas HCV genotypes 1 and 3 account for most HCV infections in Europe[65].…”

Section: Risk Factors For Ald In Chinamentioning

confidence: 99%

Growing burden of alcoholic liver disease in China: A review

Wang

Xiao

et al. 2019

WJG

View full text Add to dashboard Cite

Explosive economic growth and increasing social openness in China over the last 30 years have significantly boosted alcohol consumption, and consequently, the incidence of alcoholic liver disease (ALD) in China has increased. Because the epidemiologic and clinical features of ALD in the Chinese population may differ from those of the Caucasian population, this review describes the epidemiology, pathogenesis, genetic polymorphisms, diagnosis, and treatment of ALD in the Chinese population. This updated knowledge of ALD in China provides information needed for a global understanding of ALD and may help in the development of useful strategies for reducing the global ALD burden.

show abstract

Section: Risk Factors For Ald In Chinamentioning

confidence: 99%

Growing burden of alcoholic liver disease in China: A review

Wang

Xiao

et al. 2019

WJG

View full text Add to dashboard Cite

show abstract

“…Generally, gt1, gt2 and gt3 are distributed globally, gt4 is prevalent in Middle Eastern countries, gt5 is restricted to the northern part of South Africa, and gt6 is endemic in South‐East Asia and south China . Previously, we conducted a comprehensive study and found that HCV gt6a has become the second most prevalent subtype on Hainan Island. Other than HCV gt6a, we also identified 6 novel unassigned gt6 variants, all of which were discovered in the Li ethnic within Baisha County, Hainan Island .…”

Section: Introductionmentioning

confidence: 99%

HCV genotype 6 prevalence, spontaneous clearance and diversity among elderly members of the Li ethnic minority in Baisha County, China

Yu²,

Leitch

et al. 2019

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Summary The epidemiology of hepatitis C virus varies widely across geographical regions and ethnic groups. Our previous study showed that 6 strains isolated from Baisha County, Hainan Island, China, were all new genotype 6 (gt6) subtypes which differed significantly from subtypes of other regions. In the current study, we conducted a comprehensive epidemiological survey of HCV in the Li ethnic group, native to Baisha County. Anti‐HCV antibodies were detected by 2 independent ELISAs in all participants, and positive results confirmed by the recombinant immunoblot assay (RIBA) and HCV RNA viral loads were measured. Univariate chi‐square test and multivariable logistic regression analyses were used to determine the risk factors for HCV infection and spontaneous clearance rates. Indeterminate RIBA results were excluded or included in analyses; consequently, findings were expressed as a range. Direct sequencing of partial regions within NS5B and E1 was employed for genotyping. Among 1682 participants, 117 to 153 were anti‐HCV positive (7.0%‐9.1%), with 42.7%‐52.6% confirmed to have cleared infection. Anti‐HCV positivity was associated with older age (≥60 years) (OR = 0.02, 95% CI 0.01‐0.05, P < 0.01) and surgery (OR = 2.75, 95% CI 1.36‐5.57, P < 0.01), with no significant difference found between the HCV infection group and the HCV spontaneous clearance group. The gt6 subtype distribution characteristics of Baisha County were unique, complex and diverse. The sequences did not cluster with known gt6 subtypes but formed 4 Baisha community‐specific groups. HCV infection in members of the Li minority ethnic group is characterized by high prevalence rates in the elderly, high spontaneous clearance rates and broad gt6 diversity.

show abstract

“…Genotype 1 is the most prevalent worldwide (49.1%), followed by genotypes 3 (17.9%), 4 (16.8%) and 2 (11.0%) [2]. In China, six HCV genotypes have been found [6] and the major genotypes include genotypes 1, 2, 3, and 6 [7, 8]. The major subtypes are 1b, 2a, 3b, 6a and 3a [7, 8], accounting for 98.84% of the patient samples investigated (1b, 52.18%; 2a, 28.69%; 3b, 7.06%; 6a, 6.41% and 3a, 4.62%) [7].…”

Section: Introductionmentioning

confidence: 99%

“…In China, six HCV genotypes have been found [6] and the major genotypes include genotypes 1, 2, 3, and 6 [7, 8]. The major subtypes are 1b, 2a, 3b, 6a and 3a [7, 8], accounting for 98.84% of the patient samples investigated (1b, 52.18%; 2a, 28.69%; 3b, 7.06%; 6a, 6.41% and 3a, 4.62%) [7]. Among the HCV genotypes worldwide, genotype 3 is the second most common genotype [2].…”

Section: Introductionmentioning

confidence: 99%

“…Among the HCV genotypes worldwide, genotype 3 is the second most common genotype [2]. In China, genotype 3 is also among the major genotypes [7, 8] and is the most prevalent genotype in drug users [9]. Moreover, genotype 3 shows an increasingly wide geographic distribution over time [10] and is associated with a trend of earlier cirrhosis incidence [11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting

Han

Fan

Wang

et al. 2019

Virol J

View full text Add to dashboard Cite

Background Patients with hepatitis C virus (HCV) genotype 3 infection remain a difficult-to-cure population. This study evaluated the efficacy and safety of sofosbuvir-based regimen in genotype 3 patients in a real-world setting. Methods HCV genotype 3a-infected adults with compensated liver disease were treated with sofosbuvir (SOF)/velpatasvir (VEL) or SOF/daclatasvir (DCV) with or without ribavirin (RBV) for 12 or 24 weeks, respectively. Efficacy was measured by sustained virologic response at post-treatment week 12 (SVR12). Adverse events were evaluated throughout the treatment and follow-up course. Results A total of 41 genotype 3a-infected patients were included. Of them, 10 patients (24%) had cirrhosis, 3 (7%) had renal impairment, and 2 (5%) failed previous treatment. Nine patients (22%) were treated with SOF/VEL and 32 (78%) with SOF/DCV with or without RBV. SVR 12 was achieved in 100% (9/9) of patients treated with SOF/VEL for 12 weeks and in 97% (31/32) of those treated with SOF/DCV for 12 or 24 weeks. RBV addition and extension of treatment duration did not improve the SVR of SOF/DCV (RR: 1.04; P = 0.99 and RR: 1.09; P = 0.375, respectively). Ten patients with cirrhosis, 1 on hemodialysis and 2 with treatment-experience achieved SVR12. One treatment-naïve non-cirrhotic patient on hemodialysis treated with SOF/DCV for 24 weeks relapsed at week 8 post-treatment. No serious adverse events and relevant laboratory abnormalities were observed. Conclusion SOF/VEL and SOF/DCV are highly efficacious and well tolerated in genotype 3a-infected patients with or without cirrhosis. RBV coadministration and extension of SOF/DCV treatment appear to add no improvement for efficacy. Electronic supplementary material The online version of this article (10.1186/s12985-019-1184-y) contains supplementary material, which is available to authorized users.

show abstract

Molecular evolution of hepatitis C virus in China: A nationwide study

Cited by 15 publications

References 51 publications

Growing burden of alcoholic liver disease in China: A review

Growing burden of alcoholic liver disease in China: A review

HCV genotype 6 prevalence, spontaneous clearance and diversity among elderly members of the Li ethnic minority in Baisha County, China

High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting

Contact Info

Product

Resources

About